Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.

By M. Leon, Craig R. Smith, Michael J. Mack, R. Makkar, L. Svensson, S. Kodali, V. Thourani, M. Tuzcu, D. C. Miller, H. Herrmann and 23 more. New England Journal of Medicine, 2016

4,446 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/25b89487321bf49a3850773f12c8a1f596d03abc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Catherine M. Otto
2. Rick A. Nishimura
3. R. Bonow
4. P. O'Gara
5. Thoralf M. Sundt
6. John Erwin
7. Annemarie Thompson
8. M. Mack

Citations in the corpus

• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “IIa B-R TAVR is a reasonable alternative to surgical AVR for symptomatic patients with severe AS (Stage D) and an intermediate surgical risk, depending on patient-specific procedural risks, values, and preferences (62-65).”
• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “the oral mucosa in patients with the following (13,15,23-29):”